As of 2025-01-16, the EV/EBITDA ratio of Acceleron Pharma Inc (XLRN) is -41.25. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Acceleron's latest enterprise value is 10,456.47 mil USD. Acceleron's TTM EBITDA according to its financial statements is -253.46 mil USD. Dividing these 2 quantities gives us the above Acceleron EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.5x - 16.2x | 14.8x |
| Forward P/E multiples | 15.1x - 20.3x | 17.2x |
| Fair Price | (57.65) - (62.26) | (61.38) |
| Upside | -132.2% - -134.8% | -134.3% |
| Date | EV/EBITDA |